Guardant Health
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +16.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 7.0% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 64.5% | Better than 78% |
| Operating margin | -44.5% | Better than 9% |
| Net margin | -42.4% | Better than 9% |
| Return on equity | -4,584.5% | Better than 0% |
| Return on invested capital | -35.0% | Better than 9% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -14.6% | Better than 41% |
| 6-month return | 22.6% | Better than 85% |
| 12-month return (ex latest month) | 60.4% | Better than 88% |
| Distance below 52-week high | 23.7% | Better than 53% |
Financial Health D+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.8x | Better than 85% |
| Debt to assets | 84.9% | Better than 3% |
| Interest coverage | -106.1x | Better than 5% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 39.0% | Better than 59% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 145.59
- Open
- 143.10
- Day range
- 141.01 - 148.27
- Avg price
- 145.00
- Volume
- 2.76M
- Turnover
- 399.85M
- Turnover ratei
- 2.11%
- Volume ratioi
- 1.58
- Amplitudei
- 4.99%
- 52-week rangei
- 74.55 - 191.05
Valuation
- P/Ei
- -43.92
- P/E (TTM)i
- -39.63
- P/Bi
- -71.52
- EPSi
- -3.32
- Book value / shi
- -2.04
- Net profit
- -449.15M
- Net assets
- -275.85M
Share structure
- Market cap
- 19.73B
- Float capi
- 19.04B
- Shares out
- 135.29M
- Float sharesi
- 130.57M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2018-10-04
23.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-32.68M net over the window
Short interest
- Shares short
- 9.43M
- % of floati
- 7.03%
- Days to coveri
- 5.38
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Guardant Health (GH)?
Guardant Health last traded at 145.83. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Guardant Health's market cap?
About 19.73B.
What is the P/E ratio of Guardant Health?
The trailing twelve-month P/E is -39.63. The Valuation tab shows it against the stock's own five-year range.
Does Guardant Health pay a dividend?
Guardant Health does not currently pay a regular dividend.
Is Guardant Health a buy according to analysts?
The consensus of 19 analysts is a Buy rating, with an average 12-month price target of 202.75, which implies 39.0% upside from the current price. This is not investment advice.
What is Guardant Health's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Guardant Health a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:17 · For reference only, not investment advice and not tailored to your situation.
Guardant Health discussion 0 comments